COMMUNIQUÉS West-GlobeNewswire

Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
15/12/2025
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month [...]
Communiqué de presse : Sanofi fait le point sur le tolébrutinib dans la sclérose en plaques primaire progressive
15/12/2025
Sanofi fait le point sur le tolébrutinib dans la sclérose en plaques primaire progressive L'étude de phase 3 PERSEUS dans la sclérose en plaques primaire progressive n'a pas atteint son critère d'évaluation principal de [...]
Proton Therapy New Standard of Care for Patients with Oropharyngeal Cancer
15/12/2025
Louvain-La-Neuve, Belgium, December 15, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the [...]
La protonthérapie, nouvelle norme de soins pour les patients atteints d'un cancer de l'oropharynx
15/12/2025
Louvain-la-Neuve, Belgique, le 15 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour [...]
Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
15/12/2025
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated regulatory decision for [...]
Communiqué de presse : Sanofi fait le point sur la soumission réglementaire du tolébrutinib dans la sclérose en plaques secondaire progressive non-récurrente
15/12/2025
Sanofi fait le point sur la soumission réglementaire du tolébrutinib dans la sclérose en plaques secondaire progressive non-récurrente Les discussions en cours avec la FDA concernant la demande pour la SEPSPnr indiquent [...]
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
15/12/2025
15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, [...]
Byron Medical Announces the Product Release of BlancOne: a Science-Powered Breakthrough Redefining In-Chair Whitening Technology
15/12/2025
BRISBANE, Australia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Byron Medical is excited to announce their exclusive distribution of BlancOne, a system developed with cutting-edge photochemistry and biophotonics that is [...]
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
14/12/2025
– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET – EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage [...]
Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods
14/12/2025
Milestone enables GMP manufacturing to accelerate clinical trials and transform global vaccine delivery BRISBANE, Australia and CAMBRIDGE, Mass., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Australian biotechnology pioneer Vaxxas [...]
InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial
14/12/2025
BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the phase IIb [...]
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
13/12/2025
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT enables development of [...]
Accelerating Patient Recruitment and Research Excellence: TrialWire® Supports Endpoints Clinical Trials Day NYC 2025
13/12/2025
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire ® , the industry’s fastest, intelligent patient recruitment engine breaking the bottleneck in clinical development, proudly supported Endpoints News’ 2025 Clinical [...]
Genesis Healthcare Remains Committed to Securing Longterm Stability
13/12/2025
The skilled nursing, assisted and senior living provider reiterates dedication to a financial restructuring process centered around current and future patients, residents and staff KENNETT SQUARE, Pa., Dec. 12, 2025 ( [...]
Extendicare Announces December 2025 Dividend of C$0.042 per Share
12/12/2025
MARKHAM, Ontario, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of [...]
Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
12/12/2025
TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday [...]
Teva Releases Q4 2025 Aide Memoire
12/12/2025
TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the “Investors” page on its website. Q 4 2025 [...]
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/12/2025
CELEBRATION, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Edesa Biotech Reports Fiscal Year 2025 Results
12/12/2025
TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]

Pages